Abstract:Organophosphate esters (OPEs) can exhibit various toxicities including endocrine disruption activity. Unfortunately, the low-dose endocrine-disrupting effects mediated by estrogen receptors (ERs) are commonly underestimated for OPEs and their metabolites. Here, structure-oriented research was performed to investigate the estrogenic/antiestrogenic effect of 13 OPEs (including three metabolites) and the potential mechanism. All of the OPEs exerted antiestrogenic activities in both E-screen and MVLN assays. OPEs with bulky substituents, such as phenyl rings (triphenyl phosphate (TPP), tricresyl phosphate (TCP), diphenylphosphoryl chloride, and diphenylphosphite) or relatively long alkyl chains (dibutylbutylphosphonate (DBBP)), exerted relatively strong ER antagonism potency at micromolar concentrations. The established quantitative structure–activity relationship indicated that the antiestrogenic activities of the OPEs mainly depended on the volume, leading eigenvalue, and hydrophobicity of the molecule. Molecular docking revealed that the three OPEs with the bulkiest substituents on the phosphate ester group (TPP, TCP, and DBBP) have a similar interaction mode to the classical ER antagonist 4-hydroxytamoxifen. The correlation between the antiestrogenic activity and the corresponding ER binding affinity was statistically significant, strongly suggesting that the OPEs possess the classical antagonism mechanism of interfering with the positioning of helix 12 in the ER.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.est.0c04376?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.est.0c04376</a>.Docking scores, molecular parameters, and activity data of OPEs (Table S1); RNA isolation and reverse transcription polymerase chain reaction (RT-PCR) (Part 1); the process of QSAR development and the robustness of the QSAR model (Part 2); antiproliferation effect of each OPE in the E-screen assay under single exposure scenario (Figure S1); antiluciferase activities of OPEs after cotreatment with E2 in the MVLN assay (Figure S2); empirical distribution of R2* for the PEC50 model in the antiproliferation activity of OPEs (cotreatment with E2) in the E-screen assay (Figure S3); empirical distribution of R2* for the PEC50 model in the antiluciferase activity of OPEs (exposure alone) in the MVLN assay (Figure S4); empirical distribution of R2* for the PEC50 model in the antiluciferase activity of OPEs (cotreatment with E2) in the MVLN assay (Figure S5); and the binding modes of five OPE molecules in hERα-LBD (Figure S6) (<a class="ext-link" href="/doi/suppl/10.1021/acs.est.0c04376/suppl_file/es0c04376_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Structure-Oriented Research on the Antiestrogenic Effect of Organophosphate Esters and the Potential Mechanism

Molecular Docking, Molecular Dynamics Simulation, and Structure-Based 3D-QSAR Studies on the Aryl Hydrocarbon Receptor Agonistic Activity of Hydroxylated Polychlorinated Biphenyls.

Molecular Modeling and Molecular Dynamics Simulation Studies on the Interactions of Hydroxylated Polychlorinated Biphenyls with Estrogen Receptor-β

Thyroid Hormone Disruption by Organophosphate Esters Is Mediated by Nuclear/Membrane Thyroid Hormone Receptors: In Vitro , In Vivo , and In Silico Studies

Endocrine disrupting toxicity of aryl organophosphate esters and mode of action

In Vivo Estrogenicity of P-Phenoxyphenol and P-Pentyloxyphenol

Comparison of the mechanisms of estrogen disrupting effects between triphenyl phosphate (TPhP) and tris(1,3-dichloro-2-propyl) phosphate (TDCIPP)

In Silico Study of Molecular Mechanisms of Action: Estrogenic Disruptors among Phthalate Esters.

Potential Glucocorticoid and Mineralocorticoid Effects of Nine Organophosphate Flame Retardants

Remodeling on Adipocytic Physiology of Organophosphorus Esters in Mature Adipocytes.

The risk and impact of organophosphate esters on the development of female-specific cancers: Comparative analysis of patients with benign and malignant tumors

Mechanistic in silico modeling of bisphenols to predict estrogen and glucocorticoid disrupting potentials

Exposure Assessment of Aryl-Organophosphate Esters Based on Specific Urinary Biomarkers and Their Associations with Reproductive Hormone Homeostasis Disruption in Women of Childbearing Age.

Determination of the binding affinities of OPEs to integrin α v β 3 and elucidation of the underlying mechanisms via a competitive binding assay, pharmacophore modeling, molecular docking and QSAR modeling

A green approach coupled with molecular dynamics simulations and toxicity assays to infer the mode of action for organophosphate esters

Theoretical study on the interaction mechanism between polybrominated diphenyl ether compounds and human estrogen receptor alpha

Prenylflavonoids as nonsteroidal phytoestrogens and related structure-activity relationships.

Evaluation of the Estrogenic/Antiestrogenic Activities of Perfluoroalkyl Substances and Their Interactions with the Human Estrogen Receptor by Combining In Vitro Assays and In Silico Modeling

Toxicity pathways of lipid metabolic disorders induced by typical replacement flame retardants via data-driven analysis, in silico and in vitro approaches

House Dust-Derived Mixtures of Organophosphate Esters Alter the Phenotype, Function, Transcriptome, and Lipidome of KGN Human Ovarian Granulosa Cells

Potential Estrogenic Effects Of Phosphorus-Containing Flame Retardants